Cargando…

Inactivation of the retinoblastoma tumour suppressor pathway in premenopausal breast cancer is associated with resistance to tamoxifen

Detalles Bibliográficos
Autores principales:	Lehn, S, Landberg, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284897/ http://dx.doi.org/10.1186/bcr2294

Ejemplares similares

Role of p27 in tamoxifen response in breast cancer cell lines
por: Nilsson, S, et al.
Publicado: (2009)

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
por: Lundgren, Katja, et al.
Publicado: (2008)

Molecular prediction of tamoxifen resistance in breast cancer
por: Kok, M, et al.
Publicado: (2005)

Characterisation of the tumour suppressor gene ZAC in breast tissue
por: Valleley, EM, et al.
Publicado: (2006)

Polymorphisms, endogenous hormone levels and familial breast cancer risk in premenopausal women
por: Walker, K, et al.
Publicado: (2010)

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours
por: Cooper, WN, et al.
Publicado: (2008)

Epidemiological changes in premenopausal patients with breast cancer: a two-decade retrospective study
por: Garcia-Faura, A, et al.
Publicado: (2009)

Study of the availability of digital mammography for premenopausal women in the Valencian Breast Cancer Early Detection Program
por: Ramos, M, et al.
Publicado: (2008)

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response
por: Lehn, Sophie, et al.
Publicado: (2014)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1
por: Hiscox, S, et al.
Publicado: (2008)

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen
por: Lee, Maria, et al.
Publicado: (2020)

NRG1 is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene
por: Chua, Y-L, et al.
Publicado: (2008)

Immune profiling of breast cancer patients: relationship between tumour antigen T cell responses with suppressor and effector leukocyte populations
por: Janssen, Nicole, et al.
Publicado: (2015)

Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity
por: Stone, A, et al.
Publicado: (2008)

Differential expression of cytoplasmic and stromal β-arrestin-1 is associated with separate aspects of tumor behavior in breast cancer
por: Lundgren, K, et al.
Publicado: (2009)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Cytochrome P450 modulates the therapeutic actions of tamoxifen, as evidenced in novel breast cancer models
por: Polson, E, et al.
Publicado: (2008)

Effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial
por: Harvie, M, et al.
Publicado: (2006)

The effect of intermittent versus chronic energy restriction on breast cancer risk biomarkers in premenopausal women: a randomised pilot trial
por: Harvie, M, et al.
Publicado: (2008)

Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase
por: Serrano, Isabel, et al.
Publicado: (2013)

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
por: Saladores, P, et al.
Publicado: (2015)

Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer
por: Busch, Susann, et al.
Publicado: (2012)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

Characterization of peptide aptamers to the Anterior Gradient 2: a novel inhibitor of the tumour suppressor protein p53
por: Fourtouna, A, et al.
Publicado: (2006)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Identification of proteins and signalling pathways involved in neoadjuvant chemotherapy responsiveness of breast tumours using proteomics
por: Greenwood, CR, et al.
Publicado: (2010)

Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
por: Cohen, I., et al.
Publicado: (1994)

P02.27. Martial arts exercise improves quality of life in overweight/obese premenopausal women
por: Zhang, Y, et al.
Publicado: (2012)

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions
por: Witkiewicz, Agnieszka K, et al.
Publicado: (2014)

MFSD2A is a novel lung tumour suppressor gene whose expression is modulated by a 5’-region polymorphism
por: Colombo, Francesca, et al.
Publicado: (2010)

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
por: Herschkowitz, Jason I, et al.
Publicado: (2008)

Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation
por: Stein, T, et al.
Publicado: (2008)

Primary brain tumours following breast cancer
por: Hussain, M, et al.
Publicado: (2015)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

D133p53 isoform is a direct p53 target gene that modulates p53 tumour suppressor activity
por: Aoubala, M
Publicado: (2008)

Cell Size Checkpoint Control by the Retinoblastoma Tumor Suppressor Pathway
por: Fang, Su-Chiung, et al.
Publicado: (2006)

The Retinoblastoma Tumor Suppressor Regulates a Xenobiotic Detoxification Pathway
por: Sáenz Robles, Maria Teresa, et al.
Publicado: (2011)

Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer
por: Løkkegaard, S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jh7h2m2sfg36eag01nql580ia9